Clinical Study on Induction of Beige Adipocytes by the Rare Sugar D-Allulose

Clinical study on the induction of beige adipocytes in humans by the rare sugar D-allulose.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs061240080

Enrollment

Registered

2024-11-08

Start date

2024-11-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults obesity

Interventions

D-Allulose 5 g with each meal (15 g/day) for 8 weeks

D-Allulose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. adults who are at least 20 years of age at the time of consent 2. adults who can provide written consent to participate in this study 3. adults who have a body mass index (BMI) of at least 18.5 kg/m2 and less than 35 kg/m2 at the time of screening

Exclusion criteria

Exclusion criteria: 1. severely obese or obese with a BMI of 35 kg/m2 or higher 2. adeults who have experienced serious adverse reactions to D-alulose in the past. 3. Pregnant, parturient, lactating women or women who may become pregnant 4. adeults with severe renal dysfunction (serum eGFR less than 15 ml/min/1.73m2) 5. adeults with other serious complications 6. who are currently participating in another study 7. whose participation in the study, in the opinion of the Principal Investigator or others, would not be in the best interest of the research subjects (e.g., would be detrimental to the welfare of the research subjects) or would interfere with, limit, or confuse the evaluation specific to the clinical research protocol

Design outcomes

Primary

Measure	Time frame
FDG-PET will be taken before and after feeding 5 g (15 g/day) of the rare sugar D-allulose per meal for 8 weeks to compare changes in the accumulation of areas showing brown adipose tissue (standardized uptake value (SUV) max).	—

Secondary

Measure	Time frame
Changes in body composition including body weight, muscle mass, subcutaneous fat mass, and SMI Ratio of AUC, TIR, TAR, and TBR on continuous blood glucose meter with and without D-allulose intake AUC (Area Under Curve) TIR (Time In Range) TAR (Time Above Range) TBR (Time Below Range) Changes in blood test indices such as blood glucose, HbAc, IRI, GLP-1, lipid metabolism, and liver and kidney function Changes in oral status with and without D-allulose intake	—

Measure

Time frame

Changes in body composition including body weight, muscle mass, subcutaneous fat mass, and SMI Ratio of AUC, TIR, TAR, and TBR on continuous blood glucose meter with and without D-allulose intake AUC (Area Under Curve) TIR (Time In Range) TAR (Time Above Range) TBR (Time Below Range) Changes in blood test indices such as blood glucose, HbAc, IRI, GLP-1, lipid metabolism, and liver and kidney function Changes in oral status with and without D-allulose intake

—

Contacts

Public ContactKensaku Fukunaga

Kagawa University

fukunaga.kensaku@kagawa-u.ac.jp+81-878912230

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026